Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity

In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long‐lasting antibiotic treatments. For the clinician, the question arise...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of dermatology 2011-03, Vol.38 (3), p.216-221
Hauptverfasser: PICHLER, Werner J., DAUBNER, Barbara, KAWABATA, Tom
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 221
container_issue 3
container_start_page 216
container_title Journal of dermatology
container_volume 38
creator PICHLER, Werner J.
DAUBNER, Barbara
KAWABATA, Tom
description In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long‐lasting antibiotic treatments. For the clinician, the question arises whether these symptoms are due to cross‐reactivity, are due to a new sensitization or are a reflection of a multiple drug hypersensitivity syndrome. Based on the p‐i concept (pharmacological interaction with immune receptors), we propose that the efficient stimulation of T cells by a drug is the sum of drug–T‐cell receptor affinity and readiness of the T cell to react, and therefore not constant. It heavily depends on the state of underlying immune activation. Consequently, drug hypersensitivity diseases, which go along with massive immune stimulations and often high serum cytokine values, are themselves risk factors for further drug hypersensitivity. The immune stimulation during drug hypersensitivity may, similar to generalized virus infections, lower the threshold of T‐cell reactivity to drugs and cause rapid appearance of drug hypersensitivity symptoms to the second drug. We call the second hypersensitivity reaction a “flare‐up” reaction; this is clinically important, as in most cases the second drug may be tolerated again, if the cofactors are missing. Moreover, the second treatment is often too short to cause a relevant sensitization.
doi_str_mv 10.1111/j.1346-8138.2010.01142.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_907160270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>853677978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4912-5ef301f16c6594df5ea5c933953f8d7449e2b778acf26424b0d4cac256fffb583</originalsourceid><addsrcrecordid>eNqNkc1OwzAQhC0EoqXwCig3LqT4N3aQOCBoCwiBQCBuWK5jg0vaBjuB9u1JSOkJCfZia_3NrDwLQIRgH9V1NOkjQpNYICL6GNZdiBDF_cUG6K4fNkEXEsFiTCHvgJ0QJhDilCG4DTq4pnBdXfB87quX6HVZGB_MLLjSfbhyeRwNc-VNXBWRN0qXbj4Lh5H28xDittFQkZpl0bTKS1fkJsp-M9oFW1blweytzh54HA4ezi7i69vR5dnpdaxpinDMjCUQWZTohKU0s8woplNCUkasyDilqcFjzoXSFicU0zHMqFYas8RaO2aC9MBB61v4-XtlQimnLmiT52pm5lWQKeQogZjDP0nBSMJ5yhtP0ZLf__bGysK7qfJLiaBs1iAnsklbNmnLZg3yew1yUUv3V0Oq8dRka-FP7jVw0gKfLjfLfxvLq_NBc6v1cat3oTSLtV75N5lwwpl8uhnJhxtxd__EmGTkCw2spqk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>853677978</pqid></control><display><type>article</type><title>Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>PICHLER, Werner J. ; DAUBNER, Barbara ; KAWABATA, Tom</creator><creatorcontrib>PICHLER, Werner J. ; DAUBNER, Barbara ; KAWABATA, Tom</creatorcontrib><description>In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long‐lasting antibiotic treatments. For the clinician, the question arises whether these symptoms are due to cross‐reactivity, are due to a new sensitization or are a reflection of a multiple drug hypersensitivity syndrome. Based on the p‐i concept (pharmacological interaction with immune receptors), we propose that the efficient stimulation of T cells by a drug is the sum of drug–T‐cell receptor affinity and readiness of the T cell to react, and therefore not constant. It heavily depends on the state of underlying immune activation. Consequently, drug hypersensitivity diseases, which go along with massive immune stimulations and often high serum cytokine values, are themselves risk factors for further drug hypersensitivity. The immune stimulation during drug hypersensitivity may, similar to generalized virus infections, lower the threshold of T‐cell reactivity to drugs and cause rapid appearance of drug hypersensitivity symptoms to the second drug. We call the second hypersensitivity reaction a “flare‐up” reaction; this is clinically important, as in most cases the second drug may be tolerated again, if the cofactors are missing. Moreover, the second treatment is often too short to cause a relevant sensitization.</description><identifier>ISSN: 0385-2407</identifier><identifier>EISSN: 1346-8138</identifier><identifier>DOI: 10.1111/j.1346-8138.2010.01142.x</identifier><identifier>PMID: 21342222</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antibiotics ; Chronic infection ; Cofactors ; Cross Reactions - immunology ; Cross-reactivity ; Cytokines ; drug hypersensitivity ; Drug Hypersensitivity - etiology ; Drug Hypersensitivity - immunology ; Drugs ; flare up ; Humans ; Hypersensitivity ; Immunosuppressive agents ; Lymphocytes T ; multiple drug hypersensitivity ; Risk factors ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology</subject><ispartof>Journal of dermatology, 2011-03, Vol.38 (3), p.216-221</ispartof><rights>2011 Japanese Dermatological Association</rights><rights>2011 Japanese Dermatological Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4912-5ef301f16c6594df5ea5c933953f8d7449e2b778acf26424b0d4cac256fffb583</citedby><cites>FETCH-LOGICAL-c4912-5ef301f16c6594df5ea5c933953f8d7449e2b778acf26424b0d4cac256fffb583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1346-8138.2010.01142.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1346-8138.2010.01142.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21342222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PICHLER, Werner J.</creatorcontrib><creatorcontrib>DAUBNER, Barbara</creatorcontrib><creatorcontrib>KAWABATA, Tom</creatorcontrib><title>Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity</title><title>Journal of dermatology</title><addtitle>J Dermatol</addtitle><description>In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long‐lasting antibiotic treatments. For the clinician, the question arises whether these symptoms are due to cross‐reactivity, are due to a new sensitization or are a reflection of a multiple drug hypersensitivity syndrome. Based on the p‐i concept (pharmacological interaction with immune receptors), we propose that the efficient stimulation of T cells by a drug is the sum of drug–T‐cell receptor affinity and readiness of the T cell to react, and therefore not constant. It heavily depends on the state of underlying immune activation. Consequently, drug hypersensitivity diseases, which go along with massive immune stimulations and often high serum cytokine values, are themselves risk factors for further drug hypersensitivity. The immune stimulation during drug hypersensitivity may, similar to generalized virus infections, lower the threshold of T‐cell reactivity to drugs and cause rapid appearance of drug hypersensitivity symptoms to the second drug. We call the second hypersensitivity reaction a “flare‐up” reaction; this is clinically important, as in most cases the second drug may be tolerated again, if the cofactors are missing. Moreover, the second treatment is often too short to cause a relevant sensitization.</description><subject>Antibiotics</subject><subject>Chronic infection</subject><subject>Cofactors</subject><subject>Cross Reactions - immunology</subject><subject>Cross-reactivity</subject><subject>Cytokines</subject><subject>drug hypersensitivity</subject><subject>Drug Hypersensitivity - etiology</subject><subject>Drug Hypersensitivity - immunology</subject><subject>Drugs</subject><subject>flare up</subject><subject>Humans</subject><subject>Hypersensitivity</subject><subject>Immunosuppressive agents</subject><subject>Lymphocytes T</subject><subject>multiple drug hypersensitivity</subject><subject>Risk factors</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><issn>0385-2407</issn><issn>1346-8138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1OwzAQhC0EoqXwCig3LqT4N3aQOCBoCwiBQCBuWK5jg0vaBjuB9u1JSOkJCfZia_3NrDwLQIRgH9V1NOkjQpNYICL6GNZdiBDF_cUG6K4fNkEXEsFiTCHvgJ0QJhDilCG4DTq4pnBdXfB87quX6HVZGB_MLLjSfbhyeRwNc-VNXBWRN0qXbj4Lh5H28xDittFQkZpl0bTKS1fkJsp-M9oFW1blweytzh54HA4ezi7i69vR5dnpdaxpinDMjCUQWZTohKU0s8woplNCUkasyDilqcFjzoXSFicU0zHMqFYas8RaO2aC9MBB61v4-XtlQimnLmiT52pm5lWQKeQogZjDP0nBSMJ5yhtP0ZLf__bGysK7qfJLiaBs1iAnsklbNmnLZg3yew1yUUv3V0Oq8dRka-FP7jVw0gKfLjfLfxvLq_NBc6v1cat3oTSLtV75N5lwwpl8uhnJhxtxd__EmGTkCw2spqk</recordid><startdate>201103</startdate><enddate>201103</enddate><creator>PICHLER, Werner J.</creator><creator>DAUBNER, Barbara</creator><creator>KAWABATA, Tom</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201103</creationdate><title>Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity</title><author>PICHLER, Werner J. ; DAUBNER, Barbara ; KAWABATA, Tom</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4912-5ef301f16c6594df5ea5c933953f8d7449e2b778acf26424b0d4cac256fffb583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antibiotics</topic><topic>Chronic infection</topic><topic>Cofactors</topic><topic>Cross Reactions - immunology</topic><topic>Cross-reactivity</topic><topic>Cytokines</topic><topic>drug hypersensitivity</topic><topic>Drug Hypersensitivity - etiology</topic><topic>Drug Hypersensitivity - immunology</topic><topic>Drugs</topic><topic>flare up</topic><topic>Humans</topic><topic>Hypersensitivity</topic><topic>Immunosuppressive agents</topic><topic>Lymphocytes T</topic><topic>multiple drug hypersensitivity</topic><topic>Risk factors</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PICHLER, Werner J.</creatorcontrib><creatorcontrib>DAUBNER, Barbara</creatorcontrib><creatorcontrib>KAWABATA, Tom</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PICHLER, Werner J.</au><au>DAUBNER, Barbara</au><au>KAWABATA, Tom</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity</atitle><jtitle>Journal of dermatology</jtitle><addtitle>J Dermatol</addtitle><date>2011-03</date><risdate>2011</risdate><volume>38</volume><issue>3</issue><spage>216</spage><epage>221</epage><pages>216-221</pages><issn>0385-2407</issn><eissn>1346-8138</eissn><abstract>In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long‐lasting antibiotic treatments. For the clinician, the question arises whether these symptoms are due to cross‐reactivity, are due to a new sensitization or are a reflection of a multiple drug hypersensitivity syndrome. Based on the p‐i concept (pharmacological interaction with immune receptors), we propose that the efficient stimulation of T cells by a drug is the sum of drug–T‐cell receptor affinity and readiness of the T cell to react, and therefore not constant. It heavily depends on the state of underlying immune activation. Consequently, drug hypersensitivity diseases, which go along with massive immune stimulations and often high serum cytokine values, are themselves risk factors for further drug hypersensitivity. The immune stimulation during drug hypersensitivity may, similar to generalized virus infections, lower the threshold of T‐cell reactivity to drugs and cause rapid appearance of drug hypersensitivity symptoms to the second drug. We call the second hypersensitivity reaction a “flare‐up” reaction; this is clinically important, as in most cases the second drug may be tolerated again, if the cofactors are missing. Moreover, the second treatment is often too short to cause a relevant sensitization.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21342222</pmid><doi>10.1111/j.1346-8138.2010.01142.x</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0385-2407
ispartof Journal of dermatology, 2011-03, Vol.38 (3), p.216-221
issn 0385-2407
1346-8138
language eng
recordid cdi_proquest_miscellaneous_907160270
source MEDLINE; Wiley Online Library All Journals
subjects Antibiotics
Chronic infection
Cofactors
Cross Reactions - immunology
Cross-reactivity
Cytokines
drug hypersensitivity
Drug Hypersensitivity - etiology
Drug Hypersensitivity - immunology
Drugs
flare up
Humans
Hypersensitivity
Immunosuppressive agents
Lymphocytes T
multiple drug hypersensitivity
Risk factors
T-Lymphocytes - drug effects
T-Lymphocytes - immunology
title Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T00%3A29%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20hypersensitivity:%20Flare-up%20reactions,%20cross-reactivity%20and%20multiple%20drug%20hypersensitivity&rft.jtitle=Journal%20of%20dermatology&rft.au=PICHLER,%20Werner%20J.&rft.date=2011-03&rft.volume=38&rft.issue=3&rft.spage=216&rft.epage=221&rft.pages=216-221&rft.issn=0385-2407&rft.eissn=1346-8138&rft_id=info:doi/10.1111/j.1346-8138.2010.01142.x&rft_dat=%3Cproquest_cross%3E853677978%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=853677978&rft_id=info:pmid/21342222&rfr_iscdi=true